Traws Pharma (TRAW) News Today $1.76 -0.12 (-6.38%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.85%) As of 05:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 15, 2026 | globenewswire.comTraws Pharma (TRAW) Expected to Announce Earnings on MondayMay 11, 2026 | americanbankingnews.comTraws Pops on Hantavirus ResearchMay 9, 2026 | baystreet.caA hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gainsMay 9, 2026 | msn.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship OutbreakMay 8, 2026 | benzinga.comTraws Pharma Advances Development of Clinical Candidates for Hantavirus TreatmentMay 8, 2026 | quiverquant.comQTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsMay 8, 2026 | globenewswire.comTraws Pharma (TRAW) price target decreased by 24.14% to 5.61April 29, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Major Shareholder Purchases $998,207.43 in StockApril 29, 2026 | insidertrades.comNewtown-based Traws Pharma shares full-year results, clinical progressApril 23, 2026 | msn.comTraws Pharma, Inc. Q4 2025 Earnings Call SummaryApril 16, 2026 | finance.yahoo.comTraws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...April 16, 2026 | finance.yahoo.comTraws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027April 16, 2026 | seekingalpha.comTraws Pharma Announces Up to $60 Million Private Placement FinancingApril 16, 2026 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Q4 2025 Earnings Call TranscriptApril 16, 2026 | seekingalpha.comTraws Pharma Reports Full Year 2025 Results and Provides Business HighlightsApril 15, 2026 | globenewswire.comTraws Pharma Secures $10 Million PIPE Financing to Advance Influenza Program in Human Challenge TrialApril 15, 2026 | quiverquant.comQhVIVO shares rise 11% as influenza trial win and rebrand signal integrated strategy bearing fruitApril 14, 2026 | uk.finance.yahoo.comhVIVO inks influenza trial contract and unveils unified brand as integrated platform strategy takes shapeApril 14, 2026 | uk.finance.yahoo.comTraws Pharma Delays 10-K Amid Financing ReviewApril 10, 2026 | theglobeandmail.comTraws Pharma reports phase 2 COVID-19 data, flu program updateFebruary 24, 2026 | msn.comTraws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical holdFebruary 19, 2026 | in.investing.comTraws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for ...February 19, 2026 | markets.businessinsider.comTraws Pharma Reports Completed Clinical Results of Ratutrelvir Showing Differentiated Profile Compared to PAXLOVID® with Fewer Adverse Events and No Viral ReboundsFebruary 19, 2026 | quiverquant.comQTraws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaFebruary 19, 2026 | globenewswire.comExperimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key MilestonesFebruary 2, 2026 | msn.comTRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment?January 26, 2026 | msn.comTraws Pharma stock soars after completing COVID-19 treatment studyJanuary 26, 2026 | za.investing.comTraws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir ...January 26, 2026 | markets.businessinsider.comTraws targets stockpile nod as COVID drug outperforms Paxlovid in trialJanuary 21, 2026 | msn.comTraws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of ...January 13, 2026 | markets.businessinsider.comTraws Pharma Submits IND Application for Tivoxavir Marboxil and Reports Positive Clinical Results for Ratutrelvir in COVID-19 TreatmentJanuary 13, 2026 | quiverquant.comQTraws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 PatientsJanuary 13, 2026 | globenewswire.comTraws Pharma Approves Executive Stock OptionsDecember 19, 2025 | theglobeandmail.comTraws Pharma reports 'positive' interim data with ratutrelvir vs. PaxlovidDecember 17, 2025 | msn.comTraws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 PatientsDecember 17, 2025 | markets.businessinsider.comTraws Pharma Reports Promising Interim Data for Ratutrelvir, Showing Favorable Profile Compared to PAXLOVID™ in COVID-19 TreatmentDecember 17, 2025 | quiverquant.comQTraws Pharma (TRAW) price target decreased by 94.67% to 8.16December 6, 2025 | msn.comHC Wainwright & Co. initiates coverage of Traws Pharma (TRAW) with buy recommendationDecember 4, 2025 | msn.comTraws Pharma initiated with a Buy at H.C. WainwrightDecember 3, 2025 | msn.comTraws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline AdvancesNovember 19, 2025 | msn.comTraws Pharma Reports Third Quarter 2025 Results and Business HighlightsNovember 13, 2025 | markets.businessinsider.comChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical TrialsOctober 30, 2025 | prnewswire.comTraws Pharma’s TRX-100 Study: A Potential Game-Changer in PharmacokineticsOctober 28, 2025 | msn.comTraws Pharma’s New COVID-19 Drug Trial: A Potential Game-Changer?October 28, 2025 | msn.comDover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral ...October 22, 2025 | tmcnet.comDover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.October 22, 2025 | prnewswire.comTraws Pharma doses first patient with ratutrelvir in Phase 2 COVID studiesOctober 14, 2025 | msn.comTraws Pharma Begins Phase 2 COVID-19 Treatment StudyOctober 14, 2025 | msn.comTraws Pharma Initiates Phase 2 Trials for Ratutrelvir, a Ritonavir-Free COVID-19 Treatment, Aiming for Non-Inferiority to PAXLOVID®October 14, 2025 | quiverquant.comQ Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRAW Media Mentions By Week TRAW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRAW News Sentiment▼1.220.59▲Average Medical News Sentiment TRAW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRAW Articles This Week▼22▲TRAW Articles Average Week Get the Latest News and Ratings for TRAW and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Traws Pharma and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MediciNova News Today OKYO Pharma News Today TScan Therapeutics News Today Lifevantage News Today Entera Bio News Today ImageneBio News Today PDS Biotechnology News Today MindWalk News Today Lixte Biotechnology News Today Cingulate News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRAW) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
